08.09.20: Not intended for U.S. and UK Media

Bayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020Long-term efficacy and safety results for larotrectinib (Vitrakvi™) from an integrated data set of adult and pediatric patients with TRK fusion cancer, as well as sub-analyses in advanced thyroid and lung cancer patients / Tolerability and treatment response data from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Continued research to explore potential of marketed products, evaluating regorafenib (Stivarga™) and radium-223 dichloride (Xofigo™) in combination with immunotherapiesmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news